---
title: "Varegacestat (AL102) in Desmoid tumors: Indication"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Indication. Topics: Proposed indication in the NDA, Proposed indication in the MAA, Population of the RINGSIDE phase 3 trial: adults with progressing desmoid tumors, and Registry eligibility for RINGSIDE Part B: age 12 years and older. 4 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/indication"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Proposed indication in the NDA

> “for the treatment of adults with desmoid tumors”

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

> “In April 2026, Immunome submitted an NDA to the U.S. FDA for varegacestat for the treatment of adults with desmoid tumors.”

Source: [Immunome press release, first quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-first-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.2.5-2"></a>

### Proposed indication in the MAA

> “In October 2026, the EMA validated Immunome’s MAA for varegacestat for the treatment of adults with desmoid tumors.”

Source: [Immunome press release, third quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-third-quarter-2026-financial-results-and-provides-business-update/)

> “If approved, varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors in the European Union (EU)”

Source: [Immunome press release, EMA validation of MAA (2026)](https://investors.immunome.com/immunome-announces-ema-validation-of-marketing-authorization-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.1.2.5-3"></a>

### Population of the RINGSIDE phase 3 trial: adults with progressing desmoid tumors

> “RINGSIDE Phase 3 was a double-blind, placebo (PBO)-controlled study in adults with progressing DT per RECIST v1.1 (NCT04871282).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Adults with histologically confirmed DT that has progressed in the past 12 months per RECIST 1.1”
> “Treatment-naïve and previously treated patients”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Enrolled participants were either treatment-naïve with desmoid tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.5-4"></a>

### Registry eligibility for RINGSIDE Part B: age 12 years and older

> “≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.”
> “Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
